OSE Archives - BioTuesdays

Developments

OSE expands lusvertikimab into new immune-mediated indications

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has announced that it has selected chronic pouchitis and hidradenitis suppurativa (HS) as new key indications for lusvertikimab, a potential first-in-class IL-7R...

January 29, 2026

Developments

OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced that full efficacy and safety data from the induction period of the randomized, double-blind, placebo-controlled, Phase 2 CoTikiS study of...

February 24, 2025

Developments

OSE announces positive Phase 2 results of Lusvertikimab for UC

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced positive results from the induction period its Phase 2 study of Lusvertikimab (OSE-127), demonstrating strong efficacy and a favorable safety profile...

November 4, 2024

Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

Markets

Maxim starts OSE Immunotherapeutics at buy; PT $22

Maxim Group initiated coverage of OSE Immunotherapeutics (NXT PA:OSE) with a “buy” rating and $22 price target. The stock closed at $13.56 on June 22. Analyst Naureen Quibria, Ph.D., writes that French-based OSE has a...

June 23, 2021

Markets

HCW ups OSE Immunotherapeutics PT to €10 from €7

H.C. Wainwright raised its price target for OSE Immunotherapeutics (NXT PA:OSE) to €10 from €7, citing strong results in PD-1 refractory non-small cell lung cancer (NSCLC) from the first 100-patient cohort of the Phase...

September 22, 2020

Tag - OSE

OSE expands lusvertikimab into new immune-mediated indications

OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO

OSE announces positive Phase 2 results of Lusvertikimab for UC

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

Maxim starts OSE Immunotherapeutics at buy; PT $22

HCW ups OSE Immunotherapeutics PT to €10 from €7

Subscribe